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ABSTRACT 
 
The ichthyoses, also known as disorders of keratinization (DOK), encompass a group of 
genetic skin disorders linked by the common finding of abnormal barrier function, which 
initiates a default compensatory pathway of hyperproliferation, resulting in the 
characteristic clinical manifestation of localized or generalized scaling. 
 
Ichthyoses are a highly heterogenous group of disorders, both genetically and clinically. 
Despite the identification of causative mutations in over 50 genes, clear genotype-
phenotype correlations have been difficult to establish due to the rarity of the ichthyoses 
and because mutations in the same gene can have widely divergent phenotypes, even 
in individuals with the same disease-causing mutation.  
 
In partnership with the Foundation for Ichthyosis and Related Skin Types (FIRST), we 
have served as a major national and international referral center and recruited over 800 
kindreds with DOK, utilizing whole exome sequencing to identify novel, rare mutations 
that cause DOK, many of which represent phenotypic expansion.  
 
We systematically evaluated genotypic and phenotypic data for 407 kindreds with 
ichthyosis, the largest cohort published to date. We identified 156 novel mutations and 
assessed phenotypic features of DOK with respect to genetic diagnosis to help refine 
our understanding of this heterogeneous group of disorders (Chapter 1). Such a 
systematic classification of DOK holds promise for the development of customized 
management plans, generation of targeted therapeutics, and improved understanding of 
prognostication based on genetic diagnosis. 
 
In the process of performing a large scale genotype-phenotype characterization, we 
identified kindreds with rare clinical subtypes of ichthyosis, including Bathing Suit 
Ichthyosis (BSI), a rare disorder caused by mutations in the transglutaminase 1 gene 
(TGM1) and characterized by the restriction of scale to sites of relatively higher 
temperature such as the trunk, with cooler areas remaining unaffected (Chapter 2). We 
identified novel and recurrent mutations in sixteen subjects with BSI, the largest cohort 
published to date. Our findings expand the genotypic spectrum of BSI and the 
understanding of temperature-sensitivity of TGM1 mutations.  Increased awareness of 
temperature-sensitive TGM1 genotypes should aid in genetic counseling, and provide 
insights into the pathophysiology of TGM1 ichthyoses, and potential therapeutic 
approaches. 
 
In the course of unifying genetic and clinical data to advance the understanding of the 
different subtypes of ichthyosis, we realized the critical importance of tools to assess the 
clinical severity of ichthyosis. We designed a Visual Index for Ichthyosis Severity (VIIS) 
and tested the instrument for reliability and reproducibility using two different settings: 
one that utilized scoring of 60 test photographs by 10 dermatologists, and one with in-
person evaluations on 85 subjects by 12 dermatologists at the Foundation for Ichthyosis 
and Related Skin Types (FIRST) conference (Chapter 3). The validation process 
revealed high reliability and reproducibility for both scale and erythema and indicated 
that the VIIS performs better in person than with photographs, an important 
consideration in design of clinical trials. This index provides a tool for clinical 
phenotyping and assessment of therapeutic response for many disorders of 
keratinization.    
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INTRODUCTION 
 
The ichthyoses are rare genetic skin disorders linked by the common finding of abnormal 
barrier function, which leads to increased transepidermal water loss and compensatory 
hyperproliferation.  The unifying phenotypic feature of ichthyoses is localized or 
generalized scaling. Other clinical manifestations can include erythema, palmoplantar 
keratoderma (PPK), hypohydrosis, anhidrosis, and recurrent infections. DOK can have a 
range of possible sequelae, including ectropion, or out-turning of the eyelids, alopecia, 
deforming joint contractures, and failure to thrive Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Sequelae of inherited ichthyoses  
The range of possible sequelae of DOK includes a. Severe bilateral upper and lower 
eyelid ectropion b. Scarring alopecia c. Failure to thrive requiring gastric tube placement 
d. Deforming joint contractures e. Severe plantar keratoderma with resulting limitations 
in ambulation. Genotype is provided in each panel. 
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Although ichthyoses are primarily inherited disorders with onset at or shortly after birth, 
rare acquired forms have been reported in the setting of malignancy, nutritional 
deficiency, and autoimmune or infectious disease. Mutations in over 50 genes have 
been reported to cause ichthyoses, and these affect a host of cellular functions including 
DNA repair, lipid biosynthesis, adhesion, and desquamation as well as other pathways.1 
Despite myriad pathways for pathogenesis, each features disrupted barrier function. 
 
Epidermal barrier function is maintained by a regular pattern of epidermal renewal in 
which keratinocytes, the primary cell type of the skin, arise from a renewing stem cell 
pool and undergo a tightly regulated pattern of differentiation as they transit from the 
innermost stratum basale to the outermost stratum corneum, where they are ultimately 
sloughed off. This differentiation program is marked by site-specific expression of 
proteins and, in the suprabasal layers, the production of components necessary for the 
generation of the lipid barrier.  
 
In the process of differentiation, keratins—intermediate filaments that are responsible for 
the structural integrity of keratinocytes—are among the first proteins to be expressed in 
a tightly regulated manner, with keratin 5 and 14 expressed in the basal layer and 
keratin 1 and 10 expressed in the suprabasal layers. In stratum spinosum, the second 
innermost layer of the epidermis, components of the lipid barrier (phospholipids, 
cholesterol, sphingomyelin and glucosylceramides) are packaged into lamellar bodies, 
which are specialized organelles that house the building blocks of the lipid barrier, as 
well as enzymes essential to the processing of lipid barrier precursors. At the transition 
from stratum granulosum—the third layer of the epidermis—to stratum corneum, the 
contents of lamellar bodies are extruded into the intercellular space to form protective 
lipid sheets that are responsible for the skin’s hydrophobic barrier. 2,3 
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This overall process of differentiation results in the formation of a robust barrier in the 
stratum corneum, composed of keratinocytes (the individual bricks of the barrier) and 
inter-keratinocyte lipids (the mortar)4. Mutation in proteins essential to the formation of 
this barrier (i.e. keratins, enzymes involved in lipid synthesis) lead to the disruption of 
barrier integrity, resulting in ichthyosis.  
 
Inherited ichthyoses exhibit marked genetic and phenotypic heterogeneity, and 
advances in next-generation sequencing technology have allowed for more rapid and 
cost-effective genetic analysis, leading to the identification of novel, rare mutations that 
cause DOK. Clear large-scale genotype-phenotype correlations have been difficult to 
establish, as mutations in the same gene can present with widely divergent phenotypes, 
even within kindreds bearing the same disease-causing mutation.  
 
In 2009, the Ichthyosis Consensus Conference established a consensus 
classification for DOK based on pathophysiology, clinical manifestations, and mode of 
inheritance1. This nomenclature system divides DOK into two main groups: 1) 
nonsyndromic forms, with clinical findings limited to the skin 2) syndromic forms, with 
involvement of other organ systems.   
 
Nonsyndromic ichthyoses  
 
Common Ichthyoses 
 
Ichthyosis vulgaris (IV) and X-linked recessive ichthyosis (XLRI) are classified as the 
“common ichthyoses”, given their high prevalence. IV is the most common form of 
nonsyndromic inherited ichthyosis, with an estimated incidence of 1 in 250 births.5 
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Typically, IV is a phenotypically mild form of ichthyosis. Clinical findings usually appear 
around 2 months of age, and include generalized xerosis and fine white to gray scale 
that is most prominent on the abdomen, chest and extensor surfaces of the extremities. 
Keratosis pilaris and hyper-linearity of the palms and soles are also frequently 
associated with IV.  
 
IV is caused by autosomal dominant mutations in the filaggrin gene (FLG), which plays 
an essential role in epidermal differentiation and formation of the skin barrier. 6,7 An 
autosomal semidominant mode of inheritance has also been described, meaning that 
while individuals with heterozygous mutations have a mild phenotype, those with 
homozygous or compound heterozygous mutations can display more severe forms of 
ichthyosis.6 
 
Patients with IV are at increased risk for atopic dermatitis, asthma and allergies.8,9 This 
increased risk is likely due to disruption of barrier function, which may allow for greater 
penetration of the epidermis by potential allergens.8 
 
XLRI is the second most common form of inherited ichthyoses, with a prevalence of 
1:2000 to 1:6000 males.10 Clinical findings in XLRI are frequently indistinguishable from 
IV. Manifestations usually first appear in the neonatal period as generalized 
desquamation and xerosis, and progress to fine scaling of the trunk and extremities in 
infancy. Over time, patients develop brownish, polygonal, plate-like scale that is tightly 
adherent to the skin. XLRI is caused by mutations in the STS gene, encoding steroid 
sulfatase, on the X chromosome.11  
Autosomal Recessive Congenital Ichthyosis 
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Autosomal Recessive Congenital Ichthyosis (ARCI) is a genetically and phenotypically 
heterogenous group of disorders that includes harlequin ichthyosis (HI), lamellar 
ichthyosis (LI), and congenital ichthyosiform erythroderma (CIE). The incidence of ARCI 
has been approximated at 1 in 200,000 births.12 
 
HI is caused by loss-of-function mutations in ABCA12, which encodes an ATP binding 
cassette (ABC) transporter. ABCA12 is necessary for lipid transport into lamellar 
granules, and central to the process of cornification and lipid barrier formation.13 
Interestingly, while homozygous loss of function mutations in ABCA12 lead to HI, 
missense mutations in ABCA12 result in milder phenotypes on the LI/CIE spectrum.14 
Neonates with HI present with thick, armor-like scale with severe ectropion (eversion of 
the eyelids), eclabium (eversion of the lips), and flattening of the ears. Some patients 
with HI die during the neonatal period, but survival has been shown to improve with 
progress in neonatal intensive care and early treatment with systemic retinoids. Rajpopat 
et al. showed that 83% of HI patients treated with oral retinoids survived compared to 
24% of untreated patients.15 
 
LI and CIE represent a spectrum of disorders caused by mutations in one of nine genes: 
TGM1, NIPAL4/ICHTHYIN, ALOX12B, ALOXE3, CYP4F22, ABCA12, PNPLA1, CERS3, 
and LIPN.16  Mutations in TGM1 are the most common, and account for approximately 
32% of heritability of ARCI.17 Fischer et al. found that mutations in the five most common 
genes (TGM1, NIPAL4, ALOX12B, CYP4F22, ALOXE3, and ABCA12) account for 78% 
of ARCI cases.17 Despite this, prior studies of large cohorts of patients with ARCI 
showed that 22-40% of patients have no mutations in known genes,17,18 highlighting the 
heterogeneity of this group of disorders and the importance of continued efforts in gene 
discovery. 
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Keratinopathic Ichthyosis 
 
Keratinopathic ichthyosis is a group of disorders caused by mutations in the keratin 
family of genes. The major variant of keratinopathic ichthyosis is epidermolytic ichthyosis 
(EI). Minor variants include superficial epidermolytic ichthyosis (SEI), annular 
epidermolytic ichthyosis (AEI) and ichthyosis Curth-Macklin.  
 
EI is caused by autosomal dominant mutations in the keratin 1 (KRT1) and keratin 10 
(KRT10) genes, which play an essential role in maintaining structural integrity in 
suprabasal keratinocytes19. EI is characterized by marked skin fragility, leading to 
generalized blister formation on a background of erythroderma. Neonates present with 
blistering and erythema at birth, but symptoms improve over time. Blistering becomes 
less frequent and is usually confined to sites of trauma in adulthood. Palmoplantar 
keratoderma is often associated with EI, although it is more commonly seen in patients 
with mutations in KRT1 than KRT10.19 
 
SEI, also known as ichthyosis bullosa of Seimens, is caused by mutations in KRT2.20,21 
Phenotypic manifestations are milder compared to EI, and include blister formation in 
response to trauma and hyperkeratosis (thickening of the stratum corneum) over flexural 
areas.  
 
AEI is a rare phenotypic variant of EI that was shown by Yang et al. to be caused by a 
unique mutation in KRT10 that replaces an alanine at residue 12 with a proline.22 It is 
characterized by blister formation at birth, which later progresses to the intermittent 
development of annular polycyclic erythematous plaques on the truck and extremities.  
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Ichthyosis Curth-Macklin is another rare disorder and is caused by autosomal dominant 
mutations in KRT1.23,24 It is characterized by extensive spiky or verrucous hyperkeratosis 
over the trunk and extensor surfaces of the extremities. It may also be associated with 
severe palmoplantar keratoderma. In the past five years, 2 novel distinct causative 
mutations in KRT1 have been identified, in addition to the two mutations that were 
initially described.25,26  While both EI and Ichthyosis Curth-Macklin can be caused by 
mutations in KRT1, EI is caused by amino acid substitutions and in-frame deletions in 
the gene,27 while ichthyosis Curth-Macklin is caused by insertions or deletions that lead 
to a frameshift.23-26 
 
Syndromic ichthyoses  
 
In addition to cutaneous involvement, syndromic ichthyoses affect at least one other 
organ or system. Many causative genes have been identified for syndromic ichthyoses, 
including NSDHL (CHILD syndrome),28 EBP (Conradi-Hunermann-Happle syndrome, 
CHILD Syndrome),28,29 and ALDH3A2 (Sjogren-Larsson syndrome).30 Depending on the 
specific gene mutated, a wide range of organ systems can be involved, including the 
skeletal, nervous, endocrine, and cardiovascular systems. Many of the syndromic 
ichthyoses may present at birth with isolated cutaneous findings, highlighting the 
importance of a high degree of clinical suspicion and the usefulness of genetic analysis 
in early diagnosis of these syndromic cases.31  
 
Study of ichthyosis in Dr. Choate’s lab  
 
In partnership with the Foundation for Ichthyosis and Related Skin Types (FIRST), we 
have served as a major national and international referral center and recruited over 800 
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kindreds with DOK, utilizing whole exome sequencing to identify novel, rare mutations 
that cause DOK, many of which represent phenotypic expansion. We see patients with 
ichthyosis at a monthly ichthyosis clinic, as well as the FIRST family conferences, which 
bring together families from across the country and around the world, and provide 
access to information, expert advice, and opportunities for families to get involved in 
research. We had the pleasure of organizing a research program for the FIRST family 
conference in San Diego in 2016, where we evaluated over 150 families with ichthyosis, 
providing genetic testing, and enrolling families in the National Registry. To assess 
phenotypic manifestations of disease and analyze genotype-phenotype 
characterizations, we took standardized clinical photographs of all enrolled subjects, with 
the goal of capturing cardinal phenotypic features of disease. Examples of the 
standardizes poses used for photography are shown in Figure 2.  
 
This detailed database of genotypic, phenotypic, and clinical data for patients with 
ichthyosis has allowed us to conduct a large-scale genotype-phenotype characterization 
for 407 kindreds with ichthyosis, the largest cohort published to date. We identified 156 
novel mutations and assessed phenotypic features of DOK with respect to genetic 
diagnosis to help refine our understanding of this heterogeneous group of disorders 
(Chapter 1). In the process of performing a large scale genotype-phenotype 
characterization, we identified kindreds with rare clinical subtypes of ichthyosis, including 
Bathing Suit Ichthyosis (BSI), a rare disorder caused by mutations in transglutaminase 1 
(TGM1) and characterized by the restriction of scale to sites of relatively higher 
temperature such as the trunk, with cooler areas remaining unaffected (Chapter 2). We 
identified novel and recurrent mutations in sixteen subjects with BSI, the largest cohort 
published to date. Our findings expand the genotypic spectrum of BSI and the 
understanding of temperature-sensitivity of TGM1 mutations.   
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In the course of unifying genetic and clinical data to advance the understanding of the 
different subtypes of ichthyosis, we realized the critical importance of tools to assess the 
clinical severity of ichthyosis. We designed a Visual Index for Ichthyosis Severity (VIIS) 
and tested the instrument for reliability and reproducibility (Chapter 3). This index 
provides a tool for clinical phenotyping and assessment of therapeutic response for 
many disorders of keratinization.    
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Figure 2 Standardized photography for documentation of clinical findings. Subject 
with recessive ichthyosis due to homozygous ABCA12 mutation demonstrating standard 
poses for high resolution photography. 
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STATEMENT OF PURPOSE 
 
1. To perform a large scale genotype-phenotype characterization for 407 kindreds with 
ichthyosis, identifying novel mutations and systematically evaluating phenotypic features 
of ichthyosis with respect to genetic diagnosis to refine our understanding of this rare 
group of disorders. 
 
2. Within our cohort, to identify rare subtypes of ichthyosis, including Bathing Suit 
Ichthyosis (BSI), which is characterized by restriction of scale to sites of relatively higher 
temperature such as the trunk, with cooler areas remaining unaffected. To identify novel 
and recurrent mutations for our cohort of subjects with BSI, expanding our 
understanding of temperature-sensitive mutations.  
 
3. To design and validate a severity index for ichthyosis, a critical tool for evaluating the 
efficacy of new treatments and advancing research in ichthyosis.  
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Chapter 1: Genotype-Phenotype Correlations and Novel Mutations in 407 
Ichthyosis Kindreds 
 
ABSTRACT 
 
We identify novel mutations and systematically evaluate phenotypic features of DOK 
with respect to genetic diagnosis in a cohort of 407 kindreds with ichthyosis, the largest 
cohort published to date. We recruited over 800 subjects with ichthyoses, and performed 
gene screening, with exome sequencing employed in the remaining mutation-unknown 
cases. Clinical photographs were taken to capture phenotypic involvement and 
questionnaires were utilized to assess additional clinical manifestations. We identified a 
total of 156 novel mutations, expanding the genotypic spectrum of this group of rare 
disorders. Our systematic classification of phenotypic manifestations revealed cardinal 
features that are associated with mutations in each gene, as well as the phenotypic 
range seen within our cohort for each gene. Our analysis of clinical manifestations 
revealed that the majority of subjects with ichthyosis are born with a collodion membrane 
(69%), and identified pruritis (90%), skin pain (70%), anhidrosis (57%), and eye 
problems (57%) as common clinical features. Such a systematic classification holds 
promise for the development of customized management plans, generation of targeted 
therapeutics, and improved understanding of prognostication based on genetic 
diagnosis. 
 
METHODS 
I verified the Sanger sequencing traces for all of the mutations in the cohort, identifying 
single nucleotide polymorphism (SNPs), referencing mutations previously reported in the 
HGMD Professional Database and in the Exome Aggregation Consortium, and 
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determining which mutations are novel. Working with members of the Choate lab, I 
organized a research program for the Foundation for Ichthyosis and Related Skin Types 
(FIRST) Conference, where I recruited and consented patients, took clinical 
photographs, and obtained saliva samples for genetic analysis. I also recruited and 
consented patients, taking standardized clinical photographs and obtaining saliva 
samples, monthly at the ichthyosis clinic. I performed all of the genotype-phenotype 
correlations reported in the study, evaluating phenotypic features of the clinical 
photographs taken for our patients, assessing both cardinal features and phenotypic 
range, and creating the figures of phenotypic manifestations. I also evaluated clinical 
features by analyzing the in-depth questionnaires filled out by patients at the FIRST 
conference and at the monthly ichthyosis clinic. Part of accomplishing this task involved 
curating the paper questionnaires, and I led the effort of creating an online Oncore 
database and transferring the information into a format that would facilitate analysis. 
Using the database, I then performed the analysis on the clinical manifestations of 
ichthyosis, which is reported in this study. The genetic analysis reported in this study 
was performed by various members of the Choate lab.  
 
Subjects and samples 
The study was approved by the Yale Human Investigation Committee, consistent with 
the Declaration of Helsinki guidelines, and written informed consent was obtained from 
the subjects or their parents. Subjects with X-linked ichthyosis and ichthyosis vulgaris, 
as determined by family history and clinical manifestations and confirmed by genetic 
analysis, were excluded from the study. A total of 427 subjects and 407 kindreds were 
included in the study.  
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Each subject (or parent in the case of a child) was asked to complete a detailed 
questionnaire, including self-reporting of the phenotype at birth, clinical involvement, and 
associated systemic manifestations. Fully completed questionnaires were obtained from 
135 subjects. For subjects seen at the Foundation for Ichthyosis and Related Skin Types 
(FIRST) family conference, standardized clinical photographs were taken to capture the 
phenotypic involvement. For figures illustrating the phenotypic range, only subjects who 
were not on systemic or topical retinoid therapy were included in order to more 
accurately capture the underlying disease severity. Saliva or blood samples were 
obtained from all of the subjects for genetic analysis. 
 
Genetic Analysis 
Genetic analysis was performed on DNA isolated from the saliva or blood of index cases 
and both parents, if available. Genomic DNA was extracted using standard procedures. 
Samples were first screened for mutations in 48 genes (AAGAB, ABCA12, ABHD5, 
ALOXE3, ALOX12B, ALDH3A2, ATP2A2, ATP2C1, AQP5, CARD14, CDSN, CERS3, 
CLDN1, CYP4F22, DKC1, DSC2, DSG1, DSP, EBP, EDA, FLG, GJA1, GJB2, GJB3, 
GJB4, GJB6, KANK2, KRT1, KRT10, KRT2, KRT9, KRT16, KRT17, KRT6C, MBTPS2, 
NIPAL4, NSDHL, PNPLA1, POGLUT1, RHBDF2, RSPO1, SERPINB7, SNAP29, 
SLC27A4, SPINK5, STS, TGM1, TRPV3) via multiplex polymerase chain reaction (PCR) 
and next generation sequencing. Mutations identified by next generation sequencing 
were verified by Sanger sequencing. If no causative mutation was identified through this 
screening panel, exome sequencing was employed, allowing for identification of novel, 
rare causes of DOK.  
 
All novel mutations reported in this manuscript are not referenced as single nucleotide 
polymorphisms (SNPs) and were not found in the HGMD Professional Database 
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(http://www.hgmd.cf.ac.uk) or in the Exome Aggregation Consortium 
(http://exac.broadinstitute.org).  
 
RESULTS 
 
Self-reported demographic characteristics for subjects included in the study (n=427 
subjects) are shown in Table 1 and genotypic information described in Table 2. 298 
kindreds were found to have autosomal recessive mutations in 21 different genes, and 
109 kindreds had autosomal dominant mutations in 17 genes. Clinical characteristics for 
subset of 135 subjects who completed a detailed questionnaire are shown in Table 3.  
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Table 1 Demographic characteristics for all subjects included in the study (n=427 
subjects) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gender Male 196 45.9% 
  Female 225 52.7% 
  Unclassified 6 1.4% 
    
Ethnicity Caucasian 181 42.4% 
  Hispanic/Latino 65 15.2% 
  Asian 36 8.4% 
  Middle Eastern 24 5.6% 
  Black  18 4.2% 
 Mixed 3 0.7% 
 Native American 1 0.2% 
  Unclassified 99 23.2% 
    
Age ≥ 18 yrs 155 36.3% 
  < 18 190 44.5% 
  Unclassified 82 19.2% 
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                                         a.                                                                   b. 
 
 
 
 
 
                  c.              
                                      
 
 
 
 
 
 
 
 
 
 
Table 2 Genotypic characteristics for all kindreds included in the study (n=407 
kindreds) 
a. Genes with autosomal recessive pattern of inheritance, b. Genes with autosomal 
dominant pattern of inheritance, c. Pie chart of the most common genes in our cohort. 
Abbreviations: HET, kindreds with compound heterozygous mutations; HOM, kindreds 
with homozygous mutations 
GENE 
TOTAL 
KINDREDS  
NOVEL 
MUTATIONS 
KRT10 55 11 
KRT1 17 7 
KRT2 9 2 
CARD14 5 3 
GJB2 5 0 
DSP 3 0 
GJA1 3 0 
ATP2C1 1 1 
ATP2A2 1 0 
GJB3 2 1 
EBP 1 1 
GJB4 1 0 
DSG1 1 1 
KRT6B 1 1 
POGLUT1 1 1 
RHBD2 1 0 
TRPV3 1 0 
ZDHHC4 1 1 
  109 30 
GENE 
TOTAL 
KINDREDS  HET HOM 
NOVEL 
MUTATIONS 
TGM1 110 75 35 24 
ABCA12 39 34 5 34 
ALOX12B 38 30 8 25 
NIPAL4 33 7 26 3 
ALOXE3 19 8 11 7 
PNPLA1 12 3 9 8 
SPINK5 12 8 4 6 
CYP4F22 11 4 7 8 
ALDH3A2 5 2 3 2 
ABHD5 4 1 3 0 
MBTPS2 3 0 3 1 
CDSN 2 0 2 2 
CERS3 2 1 1 1 
CLDN1 1 0 1 1 
CSTA 1 0 1 1 
KANK2 1 0 1 1 
LIPH 1 0 1 0 
RSPO1 1 0 1 1 
SLC27A4 1 1 0 0 
SNAP29 1 0 1 0 
ST14 1 1 0 1 
  298 175 123 126 
27%
13%
10%9%
8%
5%
4%
3%
3%
3%
2%
13%
TGM1
KRT10
ABCA12
ALOX12B
NIPAL4
ALOXE3
KRT1
PNPLA1
SPINK5
CYP4F22
KRT2
OTHER
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n Collodion 
membrane 
Skin 
pain 
Pruritis Skin 
odor 
Skin 
infections 
Anhidrosis 
 
Hearing 
problems 
Eye 
problems 
Hair 
loss 
TGM1 45 87% 
(39/45) 
58%  
(25/43) 
93% 
(39/42) 
43% 
(19/44) 
47% 
(21/45) 
86% 
(6/42) 
62% 
(28/45) 
74% 
(31/42) 
51% 
(22/43) 
ALOX12B 20 100% 
(18/18) 
65%  
(11/17) 
89% 
(16/18) 
30% 
(6/20) 
35% 
(7/20) 
88% 
(14/16) 
32% 
(6/19) 
47% 
(9/19) 
21% 
(4/19) 
NIPAL4 15 50%  
(7/14) 
87%  
(13/15) 
87% 
(13/15) 
47% 
(7/15) 
20% 
(3/15) 
80% 
(12/15) 
40% 
(6/15) 
60% 
(9/15) 
7% 
(1/15) 
ABCA12 13 50%  
(6/12) 
77%  
(10/13) 
100% 
(13/13) 
54% 
(7/13) 
23% 
(3/13) 
69% 
(9/13) 
62% 
(8/13) 
69% 
(9/13) 
54% 
(7/13) 
ALOXE3 8 71%  
(5/7) 
63%  
(5/8) 
75% 
(6/8) 
25% 
(2/8) 
50% 
(4/8) 
71%  
(5/7) 
38% 
(3/8) 
75% 
(6/8) 
43% 
(3/7) 
CYP4F22 8 100%  
(8/8) 
29% 
(2/7) 
86% 
(6/7) 
50% 
(4/8) 
38% 
(3/8) 
88%  
(7/8) 
25% 
(2/8) 
38% 
(3/8) 
25% 
(2/8) 
KRT10 20 14%  
(2/14) 
95%  
(18/19) 
83% 
(15/18) 
89% 
(17/19) 
85% 
(17/20) 
82% 
(14/17) 
30% 
(6/20) 
35% 
(7/20) 
20% 
(4/20) 
KRT1 6 17%  
(1/6) 
100%  
(4/4) 
100% 
(4/4) 
100% 
(6/6) 
33% 
(2/6) 
66% (4/6) 16% 
(1/6) 
16% 
(1/6) 
16% 
(1/6) 
  135 69% 70% 90% 51% 44% 57% 45% 57% 34% 
 
 
 
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Clinical characteristics for a subset of subjects who completed a 
questionnaire (n=135 subjects) 
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Autosomal recessive mutations 
Similar to prior findings,17, 32 mutations in TGM1 are the most common in our cohort, 
accounting for 37% of heritability of the autosomal recessive cases and 27% of 
heritability of all cases within our cohort. Mutations in the 5 most common genes (TGM1, 
ABCA12, ALOX12B, NIPAL4, ALOXE3) account for 80% of the heritability of the 
autosomal recessive cases. Genotype-phenotype characterizations for the 5 most 
common autosomal recessive genes are discussed below. 
 
TGM1 
The TGM1 gene encodes tranglutaminase-1, which is an enzyme essential for the cross-
linking of proteins during the formation of the cornified envelope.33, 34 Our cohort includes 
a total of 110 kindreds with mutations in TGM1, 75 with compound heterozygous 
mutations and 35 with homozygous mutations. We identified 24 mutations in TGM1 that 
are novel and have not been described previously.  
 
Phenotypic features of subjects with mutations with TGM1 are shown in Figure 3. 
Cardinal features of ichthyosis caused by mutations in TGM1 include flat armor-like 
plates of scale, with varying degree of mild to moderate erythema.  
 
Most subjects with mutations in TGM1 were born with a collodion membrane (87%, 
n=45). Common clinical features include pruritis (93%, n=42), anhidrosis (86%, n=42), 
eye problems (74%, n=42), and hearing problems (62%, n=45). The majority of patients 
reported skin pain (58%, n=43) and alopecia (51%, n=43).  
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Figure 3 Phenotypic features of subjects with mutations in TGM1  
a. Cardinal features include flat armor-like plates of scale, with mild to moderate 
erythema b. Phenotypic manifestations range from discontinuous smoothening 
(diminished fine skin markings, shininess) with small scales (left) to confluent, large 
thick scales (right).	
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ABCA12 
The ABCA12 gene encodes an ATP-binding cassette (ABC) transporter that is crucial for 
the energy-dependent lipid transport into lamellar bodies and the integrity of the lipid 
barrier.35 Homozygous loss-of-function mutations in ABCA12 result in harlequin 
ichthyosis, a severe form of ichthyosis characterized by neonatal encasement in a thick, 
armor-like scale with associated findings of eclabium, ectropion and flattened ears. 
Missense mutations in the gene result in milder phenotypes on the lamellar ichthyosis 
(LI) and congenital ichthyosiform erythema (CIE) spectrum.  
 
Our cohort includes a total of 39 kindreds with mutations in ABCA12 (13% of heritability 
of autosomal recessive cases), 34 with compound heterozygous mutations and 5 with 
homozygous mutations. Six subjects had truncating mutations in both alleles, resulting in 
harlequin ichthyosis. We identified 34 mutations in ABCA12 that are novel and have not 
been described previously. Cardinal features of ichthyosis caused by mutations in 
ABCA12 (Figure 4) include significant (often severe) erythema with fine scale and 
variable PPK, as well as the characteristic findings of tapering digits and hyperconvex 
nails. Interestingly, all of the subjects in Figure 4 are compound heterozygous with one 
missense and one nonsense mutation. Despite this, a varying degree of erythema (mild 
to severe) is observed. 
 
Half of the subjects with mutations in ABCA12 were born with a collodion membrane 
(50%, n=12). Common clinical features include pruritis (100%, n=13), skin pain (77%, 
n=13), anhidrosis (69%, n=13), eye problems (69%, n=13), and hearing problems (62%, 
n=13). The majority of patients reported skin odor (54%, n=13) and alopecia (54%, 
n=13).  
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Figure 4 Phenotypic features of subjects with mutations in ABCA12  
a. Cardinal features include significant (often severe) erythema with fine scale and 
variable PPK, as well as the characteristic findings of tapering digits and hyperconvex 
nails. b. Phenotypic manifestations range from mild erythema, discontinuous 
smoothening with small scales (left) to severe erythema with confluent scales (right). Of 
note, both subjects in panel b are compound heterozygous with one missense and one 
nonsense mutation.	
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ALOX12B and ALOXE3  
 
The ALOX12B and ALOXE3 genes encode the lipoxygenases 12R-LOX (12R-
lipoxygenase) and eLOX-3 (epidermis-type lipoxygenase 3), respectively. The 
consecutive action of these enzymes leads to the oxygenation of ceramides, which are 
essential to the formation of the lipid barrier.36, 37 
 
Our cohort includes a total of 38 kindreds with mutations in ALOX12B (13% of heritability 
of autosomal recessive cases) and 19 kindreds with mutations in ALOXE3 (6% of 
heritability of autosomal recessive cases). We identified 25 novel mutations in ALOX12B 
and 7 novel mutations in ALOXE3.  
 
Given that the products of ALOX12B and ALOXE3 function within the same pathway, it 
is not surprising that the phenotypic manifestations caused by mutations in these 2 
genes share common features (Figures 5 and 6).  Cardinal features of ichthyosis 
caused by mutations in ALOX12B and ALOXE3 include fine scale, absence of PPK, and 
mild erythema in some subjects.  
 
Most subjects with mutations in ALOX12B and ALOXE3 were born with a collodion 
membrane (100% ALOX12B, n=18; 71% ALOXE3, n=7). Common clinical features 
include pruritis (89% ALOX12B; 75% ALOXE3), skin pain (65% ALOX12B; 63% 
ALOXE3), anhidrosis (88% ALOX12B; 71% ALOXE3), and eye problems (47% 
ALOX12B; 75% ALOXE3).  
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Figure 5 Phenotypic features of subjects with mutations in ALOX12B  
a. Cardinal features include fine scale, absence of PPK, and mild erythema in some 
subjects b. Phenotypic manifestations range from discontinuous smoothening and 
small, fine scale (left) to confluent fine scale and more significant erythema (right).  
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Figure 6 Phenotypic features of subjects with mutations in ALOXE3 
Similar to mutation in ALOX12B, cardinal features include fine scale, absence of PPK, 
and minimal to mild erythema. These features are fairly consistent within our cohort, 
with minimal variation among subjects.   
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NIPAL4 
The NIPAL4 gene encodes the NIPA-like domain containing 4 protein, thought to 
function as an Mg2+ transporter and be involved in lipid processing and lamellar body 
formation.38  
 
Our cohort includes a total of 33 kindreds with mutations in NIPAL4 (11% of heritability 
of autosomal recessive cases), 7 with compound heterozygous mutations and 26 with 
homozygous mutations. We identified 3 mutations in NIPAL4 that are novel and have not 
been described previously.  
 
Cardinal features of ichthyosis caused by mutations in NIPAL4 (Figure 7) include fine 
scale, absence of PPK, and a varying degree of erythema. Similar to prior findings,39  the 
A176D missense mutation was common in subjects with mutations in NIPAL4, 
representing 55 of the 66 alleles (83%) examined in our cohort. Interestingly, while 3 of 
the subjects in Figure 5 are homozygous for the A176D mutation, great variations in the 
degree of scale and erythema are observed in these subjects.  
 
Half of the subjects with mutations in NIPAL4 were born with a collodion membrane 
(50%, n=14). Common clinical features include pruritis (87%, n=15), skin pain (87%, 
n=15), anhidrosis (80%, n=15), eye problems (60%, n=15). 
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Figure 7 Phenotypic features of subjects with mutations in NIPAL4  
a. Cardinal features include fine scale, absence of PPK, and a varying degree of 
erythema b. Phenotypic manifestations range from barely perceptible pink erythema 
and discontinuous smoothening (left) to deep red-purple erythema with confluent 
smoothening and scale (right). Of note, all subjects depicted in this figure are 
homozygous for NIPAL4 A176D.  
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Autosomal dominant mutations 
Keratinopathic ichthyosis, a group of disorder caused by mutations in one of the keratin 
genes, accounts for 74% of the heritability of the autosomal dominant cases. Keratins 
are intermediate filaments that are essential to the formation of the cytoskeleton network 
and maintenance of epidermal integrity. Mutations in KRT10 and KRT1 are the most 
common among the autosomal dominant cases in our cohort, accounting for 50% and 
16% of the heritability, respectively. These 2 genes are essential to the structural 
integrity of the suprabasal epidermis.40  
 
Mutations in KRT10 and KRT1 most commonly result in epidermolytic ichthyosis (EI), 
characterized by diffuse erythroderma and skin fragility with blister formation during the 
neonatal period, evolving into hyperkeratosis and blistering at sites of trauma in 
adulthood. Ichthyosis Curth-Macklin is a rare phenotypic variant caused by mutations in 
KRT1, characterized by spine-like or verrucous hyperkeratosis. While mutations in KRT1 
can result in both EI and ichthyosis Curth-Macklin, EI is caused by missense mutations 
and in-frame deletions,41 while Curth-Macklin is caused by frameshift mutations.42-45 
 
Genotype-phenotype characterizations for KRT10 and KRT1 are discussed in more 
detail below. 
 
KRT10 
Our cohort includes a total of 55 kindreds with mutations in KRT10, all with heterozygous 
mutations. We identified 11 mutations in KRT10 that are novel and have not been 
described previously.  
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Phenotypic features of subjects with EI with mutations in KRT10 are shown in Figure 8. 
Cardinal features of EI caused by mutations in KRT10 include columnar hyperkeratosis, 
scale in which the vertical dimension approaches or exceeds the horizontal dimension 
(compared to flat scale seen in cases caused by mutations in one of the autosomal 
recessive gene, such as TGM1). Skin fragility is another cardinal feature, especially at 
sites of trauma. As shown in Figure 8, there may be a variable degree of underlying 
erythema. PPK is typically present and smooth with occasional focal accentuation. 
 
A minority of subjects with mutations in KRT10 were born with a collodion membrane 
(14%, n=14). Common clinical features include skin pain (95%, n=19), skin odor (89%, 
n=19), skin infections (85%, n=20), pruritis (83%, n=18), and anhidrosis (82%, n=17) 
Hearing problems (30%, n=20), eye problems (35%, n=20), and alopecia (20%, n=20) 
were less common.  
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Figure 8 Phenotypic features of subjects with mutations in KRT10  
a. Cardinal features include columnar hyperkeratosis, skin fragility, and PPK b. Skin 
findings range from discontinuous regions of hyperkeratotic surface accentuation, 
including organized or geometric exaggeration of coarse skin markings (left) to 
confluent, primarily columnar hyperkeratosis (right) c. PPK is typically present and 
smooth with occasional focal accentuation.  
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KRT1 
Our cohort includes a total of 17 kindreds with mutations in KRT1, all with heterozygous 
mutations. We identified 7 mutations in KRT1 that are novel and have not been 
described previously.  
 
Phenotypic features of subjects with mutations with KRT1 are shown in Figure 9. 
Cardinal features of EI caused by mutations in KRT1 include columnar hyperkeratosis, 
with significant involvement of the extensor surfaces of joints in some subjects. PPK is 
more severe in subjects with EI caused by mutations in KRT1 than KRT10.  
 
A minority of subjects with mutations in KRT1 were born with a collodion membrane 
(17%, n=6). Common clinical features include skin pain (100%, n=4), skin odor (100%, 
n=6), pruritis (100%, n=4), and anhidrosis (66%, n=4).  
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Figure 9 Phenotypic features of subjects with mutations in KRT1 
a. Cardinal features include columnar hyperkeratosis, skin fragility, and severe PPK b. 
Skin findings range from pink erythema with columnar hyperkeratosis (left) to confluent,	
organized or geometric exaggeration of coarse skin markings with pink erythema and 
marked skin fragility (right) c. PPK is severe in most cases.  
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DISCUSSION 
 
This study, which reports the genotype and phenotype data for 407 kindreds with 
ichthyosis, represents the largest cohort published to date. We have identified a total of 
156 novel mutations, expanding the genotypic spectrum of this group of rare disorders.  
 
While prior studies have reported on the spectrum of phenotypic and genotypic findings 
in ichthyoses,32,46-49 most were limited to specific ethnic groups and focused on particular 
ichthyosis subgroups. We aimed to capture the comprehensive spectrum of genotypes 
and phenotypes seen in ichthyosis, and reported data on an ethnically heterogeneous 
cohort with representation of all of the major genes involved in ichthyosis. 
 
The genotype-phenotype correlations in ichthyoses are complex, with significant 
variations in phenotypic severity and extent of clinical manifestations in subjects with 
mutations in the same gene. Within our cohort, even subjects bearing the same disease 
causing mutation (e.g. subjects homozygous for NIPAL4 A176D) presented with a 
spectrum of phenotypic severity, with varying degrees of both erythema and scale. This 
finding highlights the need for further research to elucidate the impact of genetic 
modifiers and/or environmental factors that may affect disease severity.  
 
Given the intrinsic complexities of genotype-phenotype correlations in ichthyoses, we 
aimed to capture the cardinal phenotypic features of each of the major genes, while 
providing the range of disease severities present in our cohort for a given gene. The 
ability to differentiate potential causative genes based on key phenotypic features may 
allow for utilization of the more time- and cost-efficient targeted sequencing of the 
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candidate gene(s), rather than sequencing a panel of ichthyosis genes or pursuing 
whole-exome sequencing.  
 
To our knowledge, this study is the first to characterize clinical features of ichthyosis 
based on the specific gene mutated. Hellstrom Pigg et al. reported frequencies of clinical 
features for the different clinical subtypes of Autosomal Recessive Congenital Ichthyosis 
(Harlequin Ichthyosis, Lamellar Ichthyosis, Congenital Icthyosiform Erythroderma, and 
Pleomorphic Ichthyosis);32 however, there is much phenotypic overlap among these 
different clinical subtypes and there has been an effort to move away from clinical 
classification and utilize ichthyosis groupings based on the gene affected.1 Our analysis 
showed that the majority of subjects with ichthyosis are born with a collodion membrane 
(69%, n=135), and identified pruritis (90%), skin pain (70%), anhidrosis (57%), and eye 
problems (57%) as common clinical manifestations. Certain findings were more common 
in subjects with specific genotypes, including skin odor in subjects with mutations in 
KRT10 and KRT1 (89% and 100%, respectively), and hearing problems with subjects 
with mutations in TGM1 and ABCA12 (62% for both).  
 
Our findings expand the mutation spectrum of ichthyoses and contribute to the 
understanding of the relationship between the genotype and the phenotypic and clinical 
findings. Such a systematic classification holds promise for the development of 
customized management plans that account for mutation-specific morbidities, and 
improved understanding of prognostication based on the genetic diagnosis.  
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Chapter 2: Expanding the Genotypic Spectrum of Bathing Suit Ichthyosis 
 
ABSTRACT 
Bathing Suit Ichthyosis (BSI) is a rare congenital disorder of keratinization, characterized 
by restriction of scale to sites of relatively higher temperature such as the trunk, with 
cooler areas remaining unaffected. Fewer than 40 cases have been reported in the 
literature. BSI is caused by recessive, temperature-sensitive mutations in 
transglutaminase 1 (TGM1). Clear genotype-phenotype correlations have been difficult 
to establish, as several TGM1 mutations have been reported both in BSI and other forms 
of congenital ichthyosis. We identify novel and recurrent mutations in sixteen subjects 
with BSI, the largest cohort published to date. We report eight TGM1 missense 
mutations that have not been previously found in BSI; five have been previously 
described in non-temperature sensitive forms of congenital ichthyosis (Arg143Cys, 
Gly218Ser, Gly278Arg, Arg286Gln, Ser358Arg) and three (Tyr374Cys, Phe495Leu, 
Ser772Arg) are novel mutations. Three probands are homozygous for Arg264Trp, 
Arg286Gln, or Arg315Leu, indicating that these mutations are temperature-sensitive. 
Seven of ten probands with a compound heterozygous TGM1 genotype have a mutation 
at either arginine 307 or 315, providing strong evidence that mutations at these sites are 
temperature-sensitive, and highlighting the importance of these residues in the 
pathogenesis of BSI. Our findings expand the genotypic spectrum of BSI and the 
understanding of temperature-sensitivity of TGM1 mutations.  Increased awareness of 
temperature-sensitive TGM1 genotypes should aid in genetic counseling, and provide 
insights into the pathophysiology of TGM1 ichthyoses, transglutaminase 1 enzymatic 
activity, and potential therapeutic approaches. 
 
 
 Marukian 40 
INTRODUCTION 
Autosomal recessive congenital ichthyosis (ARCI) comprises a spectrum of disorders. 
The major phenotypic subtypes of ARCI include lamellar ichthyosis (LI), congenital 
ichthyosiform erythroderma (CIE), and harlequin ichthyosis (HI). While ARCI is 
genetically heterogeneous with at least 9 different genes causative for the most common 
forms,16 approximately 30% of the heritability of ARCI is explained by mutations in 
TGM1.17 TGM1 encodes transglutaminase 1 (TGase-1), an enzyme involved in the 
formation of the cornified envelope.33  
 
While mutations in TGM1 most commonly cause a spectrum of LI and CIE phenotypes 
of varying severity, they also underlie bathing suit ichthyosis (BSI). BSI, a very rare form 
of ARCI with fewer than 40 reported cases, is characterized by lamellar scaling that is 
restricted primarily to the truck, neck and scalp.  Affected infants are typically born as 
collodion babies and develop more localized scaling after shedding of the membrane. 
BSI is due to the temperature sensitivity of certain TGM1 mutations.50 To date clear 
genotype-phenotype correlations have been difficult to establish due to the rarity of BSI 
and because many of the BSI mutations have also been reported in subjects with more 
generalized forms of ARCI. 
 
We identified sixteen subjects with BSI and, employing targeted sequencing, found 
mutations in TGM1 in each case. Herein we report phenotypic and genotypic data for 
this cohort.  We identified eight missense mutations newly associated with BSI, including 
three novel mutations, and employed these genotypes to make inferences about the 
temperature sensitivity of TGM1 mutations. Our findings expand the spectrum of TGM1 
mutations known to cause BSI, and the understanding of mutations related to 
temperature sensitivity.   
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METHODS 
While working on genotype-phenotype characterization, we identified a cohort of 
individuals with the limited phenotypic manifestations of BSI. I recruited and consented 
several of these patients at the FIRST conference and the monthly ichthyosis clinics, 
taking clinical photographs and obtaining saliva samples for genetic analysis. Several of 
the patients were referred to us by dermatologists across the country and around the 
world. The genetic analysis was performed by members of the Choate lab and the 
referring physician in a few cases. I verified the Sanger sequencing traces for all of the 
mutations in the cohort, identifying single nucleotide polymorphism (SNPs), referencing 
mutations previously reported in the HGMD Professional Database and in the Exome 
Aggregation Consortium, and determining which mutations are novel. I performed the 
genotype-phenotype correlations reported in the study, identifying novel and recurrent 
and determining which mutations are temperature-sensitive. 
 
Subjects and samples 
The study was approved by the Yale Human Investigation Committee, consistent with 
the Declaration of Helsinki guidelines, and written informed consent was obtained from 
the subjects or their parents. A detailed clinical history was obtained from each subject, 
including phenotypic presentation at birth and evolution of disease when available. Self-
reporting of ethnicity was obtained to evaluate founder effect.  Saliva samples were 
obtained from all of the subjects for genetic analysis. 
 
Genetic analysis 
Genetic analysis was performed on DNA isolated from saliva of index cases and both 
parents, if available. DNA was extracted using standard procedures. Samples were 
either screened for mutations in eleven genes including ABCA12, ALOXE3, ALOX12B, 
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CYP4F22, NIPAL4, PNPLA1, SPINK5, TGM1, KRT1, KRT2E, and KRT10 via multiplex 
PCR and next generation sequencing, or the coding exons of TGM1 were amplified 
using polymerase chain reaction (PCR) and subsequently examined via Sanger 
sequencing.  
 
RESULTS 
BSI phenotypes and TGM1 genotypes of each subject are described in Table 4.  
Representative photos are provided in Figure 10 (Subjects 8 and 15), and the location 
of mutations relative to TGM1 protein domains are shown in Figure 11.  
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Table 4. TGM1 mutations causing BSI in sixteen subjects 
Fourteen of 16 subjects presented at birth with a collodion membrane. All eventually 
developed the characteristic phenotypic pattern seen in BSI, with scaling most prominent 
on the scalp, neck and trunk and with sparing of the central face and distal extremities. 
We report eight missense mutations not previously found in BSI. Five have been 
previously shown to cause ARCI and three are novel mutations.  
 
* Mutations not previously found in BSI 
1 Novel mutations  
Temperature-sensitive mutations are shown in red. 
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Figure 10. Clinical features of BSI 
Representative photos of the BSI phenotype, notable for plate-like scaling of the truck 
and back, with sparing of the extremities and buttocks.  (A) Subject 8.  (B) Subject 15.  
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Figure 11. Protein schematic of TGM1 mutations found in BSI 
Thirteen mutations are located in the catalytic core, two in the ß-sandwich domain, and 
one in the ß-barrel 2 domain. Nine lead to substitution of charged residues. 
 
* Mutations not previously described in BSI  
1Novel mutations 
Temperature-sensitive mutations are shown in red. 
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Homozygous TGM1 Arg264Trp, Arg286Gln, and Arg315Leu mutations are 
temperature-sensitive 
Subject 1 is the child of first cousins. He was born with a collodion membrane, and later 
developed large brown scales on the back, chest and groin, with sparing of the face and 
extremities. He is homozygous for a TGM1 Arg286Gln missense mutation. Arg286Gln 
was previously reported in a compound heterozygous state with Gly278Arg (found in 
Subject 9 and discussed below) in LI,51 but has not been previously reported in BSI.  
 
Subjects 2 and 3 are siblings and the children of second cousins.  Both were born with 
normal skin at birth and no collodion membrane, and went on to develop plate-like scale 
restricted to the neck, scalp, trunk, and flexural areas of upper extremities. Non-scarring 
alopecia is present in both subjects. Both siblings are homozygous for a TGM1 
Arg264Trp missense mutation, which has previously been found in a compound 
heterozygous state in a patient with BSI.50 It was also found in a heterozygous state in 
Patient 4, a female with TGM1 mutations Arg264Trp and Gly278Arg. The Gly278Arg 
mutation has been previously described in both LI51 and in self-healing ichthyosis, a rare 
form of ARCI characterized by the presence of a collodion membrane at birth with 
spontaneous healing of the phenotype within the first few weeks.52, 53 
 
Subjects 5 and 6 are African-American siblings, with no known consanguinity in the 
family.  Both were born with a collodion membrane and later developed plate-like scale 
restricted to the scalp and truck. They are both homozygous for a TGM1 Arg315Leu 
mutation, which has been reported by Arita et al. in a cohort of 8 South African BSI 
subjects.54, 55 
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The observation of homozygous mutations in these five subjects with BSI provides 
evidence that these TGM1 mutations (Arg264Trp, Arg286Gln, and Arg315Leu) result in 
temperature sensitivity.  All fall within the catalytic core of the transglutaminase 1 
enzyme (Figure 9).  
 
Temperature-sensitive substitutions at R315 TGM1 are common compound 
heterozygote mutations in BSI 
Subjects 7 and 8 are siblings.  Both were born with a collodion membrane and were 
noted to have thickened, fragile skin at birth. They developed dark plate-like scaling, 
most prominent on the back, chest, and neck. Both are compound heterozygous for 
TGM1 Arg315Leu, a temperature-sensitive mutation described above, and Ser772Arg, a 
novel mutation falling within the ß-barrel 2 domain (Figure 11). 
 
Subject 9 is male born with a collodion membrane and ectropion. He now has brown 
plate-like scales that are most prominent on the neck, scalp and trunk, with sparing of 
the face and the extremities. He also exhibits attention deficit hyperactivity disorder and 
developmental delay. He is compound heterozygous for TGM1 (Arg315His and 
Gly278Arg).  While both mutations fall within the catalytic core, Arg315His affects the 
same residue as Arg315Leu (found in subjects 5-8 and described above), and has been 
commonly reported in subjects with BSI.50, 56 The Gly278Arg mutation was also found in 
Subject 4.  
 
Subject 10 is a male born with a collodion membrane, and later developing scaling 
restricted to the scalp and trunk. He has TGM1 mutations Arg315His and c.876+2 T>C, 
a mutation within the donor splice site of exon 5 previously described in generalized 
ARCI.57  
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The observation of a missense mutation at R315 in six of our 16 BSI subjects highlights 
the prevalence of substitutions at this site in BSI, and contributes to evidence that such 
mutations are temperature-sensitive. 
 
TGM1 Arg307Gly is a common BSI mutation and is temperature-sensitive 
Subject 11 is a female born with a collodion membrane that peeled at a few weeks of 
age, and developed thick dark scale on the scalp, neck, axillae, and groin by 1 year of 
age. She is compound heterozygous for TGM1 Arg307Gly, which has been commonly 
described in BSI,50,56 and c.877-2 A>G, a mutation within the acceptor splice site of exon 
6, which has previously been found in BSI in conjunction with Arg307Gly (as in Subject 
11) as well as with Arg264Trp and Arg315His in our cohort.50,56   
 
Subject 12 is a male born with a collodion membrane. He now has brown plate-like 
scales that are most prominent on the neck, scalp, axillae, and trunk.  He is compound 
heterozygous for TGM1 Gly218Ser and Arg307Gly. The Gly218Ser mutation has been 
previously reported in an LI subject with a collodion membrane at birth and later 
development of thick scales and ectropion.58  
 
Subject 13 is a female born with a collodion membrane. She now has thick dark scale 
restricted to the neck, scalp and truck. She has TGM1 mutations Arg307Gly and 
Ser358Arg. The Ser358Arg mutation has been previously reported in two siblings with 
LI, who were born with collodion membranes and later developed generalized scaling 
with facial and palmoplantar involvement.59, 60 
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Subject 14 is a female born with a collodion membrane, later developing scaling 
restricted to the trunk and scalp. She has TGM1 mutations Arg307Gly and Tyr374Cys. 
The Tyr374Cys mutation is within the catalytic domain and has not been described 
previously. 
 
The observation of the Arg307Gly mutation in four out of our sixteen BSI subjects 
contributes to evidence that Arg307Gly is relatively common in BSI, and is a 
temperature-sensitive mutation. 
 
TGM1 Phe495Leu is a temperature-sensitive mutation 
Subject 15 is a male born with a collodion membrane. He now has thick scale restricted 
to the neck, scalp and truck, as well as flexural involvement of the extremities. He has 
TGM1 mutations Arg143Cys and Phe495Leu. Homozygosity for the Arg143Cys mutation 
has been previously described in two patients with LI.58 We therefore presume that 
Phe495Leu, which is novel, is the temperature-sensitive mutation in this subject. 
 
TGM1 Ile469_Cys471delinsMetLeu is a novel mutation in the catalytic core 
Subject 16 is a female born with a collodion membrane. She now has scale restricted to 
the neck, scalp and trunk. She has TGM1 mutations Gly291Asp and 
Ile469_Cys471delinsMetLeu. The Gly291Asp mutation was previously described in a 
compound heterozygous state in a patient with BSI,61 as well as a patient with 
generalized ARCI.62 The TGM1 Ile469_Cys471delinsMetLeu is a novel in-frame indel 
mutation that affects the catalytic core.  
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DISCUSSION 
BSI is a rare ARCI phenotype characterized by presentation at birth with a collodion 
membrane, followed by clinical improvement of ichthyosis on the face and extremities 
during the first few weeks of life. The resulting phenotype of scaling restricted to the 
trunk, neck, and scalp is a distinguishing feature of BSI, and can be differentiated from 
somatic mosaicism by the lack of a distribution pattern along Blaschko’s lines.  
 
Prior to this report, 21 missense mutations had been reported in BSI subjects. Of these, 
9 had been reported only in subjects with BSI, while 12 had been observed in both BSI 
and generalized ARCI.62 Both truncating mutations (nonsense, splice site, and 
frameshift) and missense mutations in TGM1 have been found in subjects with BSI.50, 54, 
56, 61, 63, 64 However, while homozygosity or compound heterozygosity for truncating 
mutations has been observed in generalized forms of ARCI,59, 65, 66 such a genotype has 
never been observed in BSI. This is consistent with the hypothesis that near or total loss 
of TGase-1 function causes generalized forms of ARCI, while genotypes that include a 
missense mutation resulting in a partially active, temperature-sensitive TGase-1 result in 
the more limited BSI phenotype. 
 
In 2006, Oji et al. investigated TGase-1 enzymatic activity in BSI tissue, assessing 
uptake of biotinylated cadaverine into cornified envelopes, finding that areas of healthy 
skin in patients with BSI show nearly normal TGase-1 activity, while affected areas 
display clearly reduced and abnormal activity. Furthermore, digital thermal imaging 
showed close association between skin temperature and the degree of scaling in 
patients with BSI, with warmer body sites exhibiting greater scaling. Functional TGase-1 
testing of normal-appearing skin of a BSI subject homozygous for the missense mutation 
Tyr276Asn showed clear temperature-sensitivity, with reduction in enzyme activity at 
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37˚C compared to 25˚C. This may explain the increased degree of scaling at sites of 
relatively higher temperature, such as the trunk.50  
 
In addition to the TGM1 mutation Tyr276Asn, several other mutations have been 
previously presumed to be temperature-sensitive based on their presence in a 
homozygous state in subjects with BSI, including TGM1 mutations Ile304Phe, 
Arg307Gly, Arg315Leu, Arg315His, Val383Met, Arg687His.50, 54-56, 61, 63, 67 
 
Here we report phenotypic and genotypic data from 16 subjects with BSI, the largest 
cohort published to date.  Aside from a pair of siblings who had normal skin at birth with 
no collodion membrane (subjects 2 and 3), the phenotypes were consistent with prior 
descriptions of BSI. We identified a total of 16 unique mutations in our cohort, including 
13 missense, two splice site, and one indel mutation. Eight of the missense mutations 
have not been previously reported for BSI; of these, five have been previously described 
in generalized ARCI (Arg143Cys, Gly218Ser, Gly278Arg, Arg286Gln, Ser358Arg), while 
three (Tyr374Cys, Phe495Leu, Ser772Arg) are novel mutations. The indel mutation 
TGM1 I469_C471delinsML is also novel.  
 
Tranglutaminase 1 consists of three domains: an N-terminal ß-sandwich domain, a 
catalytic core domain, and two C-terminal ß-barrel domains.68 Most BSI mutations have 
been located in exons 5 and 6 of TGM1, encoding the N-terminal portion of the catalytic 
core domain.50 Of the 13 unique missense mutations reported in this study, only two are 
within the ß-sandwich domain (Arg143Cys, Gly218Ser) and one is within the ß-barrel 2 
domain (Ser772Arg).  In stark contrast, ten are within the catalytic core (Arg264Trp, 
Gly278Arg, Arg286Gln, Gly291Asp, Arg307Gly, Arg315His, Arg315Leu, Ser358Arg, 
Tyr374Cys, Phe495Leu), including all three of the mutations homozygous in our BSI 
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subjects. (Figure 9). All of our BSI subjects have at least one mutation within the 
catalytic core, and catalytic core mutations represent 88% of the mutations in our 
unrelated probands (23 of 26 alleles). Given that the catalytic core is only 38% of the 
total protein, our findings underscore a striking clustering of BSI mutations in this 
domain.  
 
Based on our observation of BSI subjects homozygous for TGM1 mutations Arg264Trp, 
Arg286Gln, and Arg315Leu, we conclude that these mutations are temperature-
sensitive. Furthermore, the recurrence of mutations affecting R307 and R315 in our 
cohort, which among unrelated probands are present in 1/3 of homozygotes and 7/10 of 
compound heterozygotes, comprising 35% of the mutations (9 out 26 total alleles), 
bolsters prior evidence that these mutations are common in BSI (also reported by 
Bourrat et al.),56 and temperature-sensitive.  Finally, we hypothesize that the novel 
mutation Phe495Leu is temperature-sensitive, given that the TGM1 genotype of subject 
15 includes this mutation and Arg143Cys; the latter mutation is presumably not 
temperature-sensitive given that subjects homozygous for Arg143Cys are described as 
exhibiting generalized LI.58  
 
Though our findings provide evidence for temperature sensitivity of TGM1 mutations, 
clear genotype-phenotype correlations have been difficult to establish, as several TGM1 
mutations have been reported in both BSI and generalized ARCI. For example, 
homozygosity for Arg315Leu has been found in a pair of twins who were described as 
having lamellar ichthyosis, whose phenotype at two months of age included thick plate-
like scaling affecting the truck and extremities, with sparing of the face.69 Another patient 
described as having characteristic phenotypic findings of lamellar ichthyosis was found 
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to be compound heterozygous for TGM1 mutations, including Arg286Gln, which we 
describe here as temperature-sensitive.51 
 
The reporting of these mutations in both BSI and generalized ARCI may represent 
evolution of the phenotype, as patients with BSI can present with more generalized 
scaling earlier in life, with appearance of a bathing-suit distribution later in childhood. 
Thus, phenotypic characterization within the first few months of life may lead to 
misclassification. This dynamic nature of BSI highlights the importance of continued 
follow-up of subjects with presumed temperature-sensitive mutations, with phenotypic 
re-evaluation at multiple ages.  Additional environmental or genetic factors that may 
determine the level of enzyme activity and response to temperature in subjects with 
TGM1 mutations remain unclear. 
 
Patients with BSI typically respond well to agents that improve barrier function and 
promote desquamation, including keratolytics and topical or systemic retinoids.  Topical 
tazarotene led to substantial improvement in two subjects within our cohort.   
  
Our findings expand the genotypic spectrum of BSI, and provide evidence supporting the 
temperature sensitivity of specific TGM1 mutations (Arg264Trp, Arg286Gln, Arg307Gly, 
Arg315Leu, Arg315His, Phe495Leu), which are clustered in the catalytic core. Although 
patients respond well to topical and systemic therapies, further research into the 
pathogenesis of BSI could lead to the development of novel therapeutic approaches 
targeting enzymatic stability and consideration of environmental modifications that might 
modify disease severity.   
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Chapter 3: Establishing and Validating an Ichthyosis Severity Index 
 
ABSTRACT 
 
We designed and validated a Visual Index for Ichthyosis Severity (VIIS) for scale and 
erythema that provides 1) written descriptions of the features characteristic of each level 
of severity 2) visual standards for 4 body sites, and 3) two distinct standards to account 
for different types of scale. We tested the VIIS for reliability and reproducibility using two 
different settings: one that utilized scoring of 60 test photographs by 10 dermatologists, 
and one with in-person evaluations on 85 subjects by 12 dermatologists at the 
Foundation for Ichthyosis and Related Skin Types (FIRST) conference. The validation 
process revealed high reliability and reproducibility for both scale and erythema. The 
inter-rater and intra-rater ICCs for scale were consistently near or greater than 0.7 in 
both settings. By contrast, the inter-rater reliability for erythema was higher during in-
person validation compared to validation on test photographs. Our analysis indicates 
that the VIIS performs better in person than with photographs, an important 
consideration in design of clinical trials. Power analysis predicts that a 1-step difference 
on this 5-step scale would be detectable with 12 subjects in each of two defined groups.  
This index provides a tool for clinical phenotyping and assessment of therapeutic 
response for many disorders of keratinization.    
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INTRODUCTION 
Careful examination of patients who have ichthyosis reveals that the amount of scale on 
specific sites is quite variable, and that there are subtle differences in the quality of scale 
between different genotypes.  While textbooks often suggest a monomorphous 
presentation for different types of ichthyosis, our experience from carefully 
photographing and genotyping over 500 individuals with ichthyosis shows significant 
patient to patient variability in amount of scale at any given body site.  Previous 
estimates of scale severity have been limited by focus on a single body site,71 by 
examples of severity that utilize different body sites as comparators,72 or by 
concentration on a single phenotype.73 
 
Erythema is often a clinically significant component of ichthyosis even though the 
relative roles of vasodilation and inflammation are not well understood.  Erythema is an 
important component of many skin diseases, but there is no agreement as to how its 
severity should be measured.  Strong arguments have been made for the clinical validity 
of visual analog scales,74, 75 or the superiority and sensitivity of reflectance 
spectroscopy.76-78 To our knowledge, all measurements of erythema in ichthyosis have 
used a visual analog scale without critical validation.    
 
A reliable method of assessing the clinical severity of subjects with ichthyosis is critical 
to evaluating the efficacy of new treatments and to grading the severity of ichthyosis due 
to mutations in a single gene and between different genes. Although prior studies have 
used visual scales to measure the clinical severity of this rare group of disorders,71-73, 79, 
80 to date, no widely-accepted index exists.  
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Our goal was to develop a severity index that could be used across many types of 
ichthyosis and many body sites without requiring separate scales for each body site, 
genotype or phenotype. 
We aimed to create severity index using photographs and detailed written descriptions 
for the degree of scale and erythema in ichthyosis.  
 
We designed a prospective study to evaluate the reliability and reproducibility our 
instrument, the Visual Index for Ichthyosis Severity (VIIS), using two different settings: 
one that utilized scoring of test photographs and one with in-person evaluations.  
 
METHODS 
While working on the genotype-phenotype characterization, we identified the need for a 
reliable method to assess ichthyosis severity. Working with Dr. Choate and Dr. Milstone, 
we identified photographs that were representative of each level of severity, and created 
detailed written descriptions for each level of severity. I recruited and consented patients 
at the FIRST conference and the monthly ichthyosis clinics, taking standardized clinical 
photographs. Working with Dr. Choate and Dr. Milstone, I led both stages of validation. 
Statistical analysis was performed by Yanhong Deng and Geliang Gan from the Yale 
Center for Analytical Sciences. 
 
Study Design 
To design a user-friendly tool, we developed photographic standards for two 
characteristics of ichthyosis: scale and erythema. For scale, photographic standards for 
four representative body sites that are typically less aggressively groomed (upper arm, 
upper back, lower leg and dorsal foot) were created. Each of the four representative 
body sites was carefully defined using anatomical landmarks. Two different sets of scale 
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standards were developed: the lamellar (“L”) set of standards for the typical flat scales 
that are seen in most forms of ichthyosis and the keratoderma (“K”) set for the more 
columnar scales that are typical of epidermolytic ichthyosis and erythrokeratodermas. 
We employed five-point Likert scales (0-4) with increasing clinical severity. The 
combined scores, therefore, range from 0 to 16 (score of 4 for all 4 body sites) for each 
category (erythema and scale). The final score accounts for both erythema and scale, 
and ranges from 0 to 32. Each photographic standard includes representative clinical 
photographs for each severity score, along with detailed written descriptions of features 
characteristic of the severity score represented. All of the clinical photographs were 
obtained at Foundation for Ichthyosis and Related Skin Types (FIRST) family 
conferences. The photographs included in the standards were limited to subjects with 
Fitzpatrick 1-3 skin type. Photographs were chosen with the aim of demonstrating 
severity alone. All of the photographic standards can be found in the Appendix.  
 
Validation of our instrument was performed in two stages the first utilized scoring of test 
photographs, and the second involved in-person evaluations. During the first stage, ten 
dermatologists were provided with a series of 60 test photographs (15 photographs for 
each of the 4 body sites) and asked to independently use our index to score for scale 
and erythema (Stage 1, Round 1). The re-shuffled photographs were sent to the same 
dermatologists four weeks later (Stage 1, Round 2) to determine intra-rater reliability. 
This four-week interval was chosen to reduce rater recall of prior scoring.71  
 
The second stage of validation was performed at the FIRST family conference in San 
Diego in June 2016. Eligible participants included all subjects enrolled in the National 
Registry for Ichthyosis and Related Skin Types who participated in a clinical screening 
appointment at the conference. None refused to participate. Subjects were seen in one 
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of three clinical evaluation rooms with four dermatologists assigned to each room. A total 
of twelve dermatologists participated, and they were asked to independently rate the 
clinical severity of the subjects seen in their room. The rating process was limited to the 
first 5 minutes of each twenty minute appointment. Discussion of ratings was not 
permitted and all raters attested that they adhered to this requirement. Four (two in room 
2 and two in room 3) out of the twelve dermatologists had previously participated as 
raters during the validation on test photographs. 
 
Participants 
 
The study was approved by the Yale Human Investigation Committee, consistent with 
the Declaration of Helsinki guidelines, and written informed consent was obtained from 
the participants or their parents. Each participant was asked to fill out a questionnaire, 
including self-reporting of gender, age, ethnicity, and ichthyosis type. 
 
Statistical analysis 
 
Intra-rater Intraclass Correlation Coefficients (ICCs) for agreement were estimated using 
the one-way random model. The estimated ICCs are the variances contributed by the 
different subjects divided by the summation of variances contributed by subjects and the 
variances of random error. Combined intra-rater ICCs were estimated using the mixed 
model controlling for raters. Inter-rater ICCs for agreement were estimated using the 
two-way random model. The estimated ICC is the variance contributed by the different 
subjects divided by the summation of the variance contributed by subjects, variance 
introduced by the raters and the variance of random error. Inter-rater ICCs for 
consistency were estimated using the two-way random model as well. The estimated 
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ICC is the variance contributed by the different subjects divided by the summation of the 
variance contributed by the subjects and the variance of random error. ICCs less than 
0.7 were considered unacceptable, 0.7 – 0.79 fair, 0.8 – 0.89 good, and greater than or 
equal to 0.9, excellent.11 The reliability of choosing the “L” or “K” standard by the same 
rater was estimated by the Cohen’s Kappa, which is a measure of intra-rater reliability 
for a nominal variable. The reliability of choosing the “L” or “K” standard on same subject 
across all raters was estimated by the Kuder-Richardson Formula 20, which is a 
measure of inter-rater reliability for a nominal variable. All confidence intervals were 
calculated at 95% confidence level. For the power analysis, a two-sided two-sample t-
test was performed with a significance level (alpha) of 0.05. All analyses were carried 
out using SAS 9.4.3 (SAS Institute, Cary, NC). 
 
RESULTS 
 
Validation of VIIS on test photographs (Stage 1) 
 
A total of 60 photographs (15 for each body site) were sent to ten dermatologists for 
baseline scoring (Stage 1, Round 1). All raters were experts in ichthyosis, and members 
of the FIRST Medical & Scientific Advisory Board (MSAB). The re-shuffled photographs 
were re-sent in four weeks to test reproducibility (Stage 1, Round 2). Demographic and 
clinical details for the subjects whose photographs were used as the test images can be 
found in Table 5. 
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Table 5. Demographic and clinical characteristics for patients whose photographs 
were used for the first stage of validation (n=60) 
Abbreviations: EI, Epidermolytic Ichthyosis; LI, Lamellar Ichthyosis; CIE, Congenital 
Icthyosiform Erythroderma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		 		 Upper	Back	 Upper	Arm	 Lower	Leg	 Dorsal	Foot	 Total	
		 		 		 		 		 		 n	 %	
Gender	 Male	 5	 6	 5	 5	 21	 35.0%	
		 Female	 10	 9	 10	 10	 39	 65.0%	
		 		 		 		 		 		 		 		
Ethnicity	 Caucasian	 12	 11	 11	 11	 45	 75.0%	
		 Hispanic/Latino	 1	 1	 0	 1	 3	 5.0%	
		 Black	 0	 1	 1	 0	 2	 3.3%	
		 Unknown	 2	 2	 3	 3	 10	 16.7%	
		 		 		 		 		 		 		 		
Age	 ≥	18	yrs	 9	 8	 6	 7	 30	 50.0%	
		 <	18	 6	 7	 9	 8	 30	 50.0%	
		 		 		 		 		 		 		 		
Ichthyosis	Type	 		 		 		 		 		 		 		
		 EI	 5	 4	 6	 6	 21	 35.0%	
		 ARCI	 6	 7	 6	 7	 26	 43.3%	
		 Netherton's	 1	 0	 0	 1	 2	 3.3%	
		 Ichthyosis	vulgaris	 0	 1	 1	 0	 2	 3.3%	
		 Normal	control	 1	 1	 0	 0	 2	 3.3%	
		 Unclassified	 2	 2	 2	 1	 7	 11.7%	
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Inter-rater reliability was higher for scale than for erythema 
Descriptive statistics for inter-rater reliability (IRR) for scale and erythema can be found 
in Figure 12. Two measures of IRR were evaluated: ICC for agreement, which is the 
more rigorous metric and requires absolute agreement among the raters, and ICC for 
consistency, which measures whether the raters provide scores that have the same rank 
order rather than requiring agreement on the absolute values. ICCs for consistency are 
especially relevant when evaluating a change in severity from baseline, such as 
assessing response to treatment. As expected, ICCs for consistency are higher than 
ICCs for agreement for the same data points. For both rounds 1 and 2, the ratings were 
found to be significantly correlated for scale (ICCs near 0.7 or greater). However, the 
inter-rater reliability for erythema was poor (ICCs < 0.7).  
 
Raters were consistent in choosing the specific set of scale standards for a given subject 
Raters were given two separate sets of scale standards (lamellar or “L” set of standards 
and keratoderma or “K” set of standards) to account for the two different types of scales 
most commonly seen in subjects with ichthyosis. Raters were consistent in choosing a 
set of standards (“L” or “K”) for a given patient, and there was excellent inter-rater 
reliability for all body sites during both rounds of testing (Kuder-Richardson Formula 20 > 
0.9) Table 6. There was also high intra-rater reliability between Round 1 and Round 2 
for the same rater, with Kappa near or greater than 0.7 for all body sites.  
 
Intra-rater reliability was higher for scale compared to erythema 
To determine intra-rater reliability, we employed a test-retest approach with a 4-week 
interval between Rounds 1 and 2. Across all ten raters, the intra-rater ICC was 0.75 (CI 
0.60, 0.90) for scale and 0.59 (CI 0.39, 0.79) for erythema. 
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Figure 12. IntraClass Correlation Coefficients (ICCs) for agreement and 
consistency for the two rounds of photographic testing (Stage 1, Rounds 1 and 2) 
For both rounds of testing, the ratings were significantly correlated for scale (ICCs near 
0.7 or greater). The inter-rater reliability for erythema was lower (ICCs less than 0.7).  
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 ROUND 1 ROUND 2 
Dorsal Foot 0.95 (0.89, 0.98) 0.95 (0.89, 0.98) 
Lower Leg 0.94 (0.88, 0.98) 0.91 (0.82, 0.96) 
Upper Arm 0.90 (0.81, 0.96) 0.92 (0.83, 0.97) 
Upper Back 0.92 (0.85, 0.97) 0.94 (0.89, 0.98) 
 
Table 6. Kuder-Richardson Formula 20, KR20, values for the two rounds of 
photographic testing (Stage 1, Rounds 1 and 2) 
Raters were consistent in choosing the specific set of standards for scale (“L” or “K”) for 
a given patient, with excellent inter-rater reliability for all body sites (KR20 > 0.9). 
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Live validation of VIIS at the FIRST conference (Stage 2) 
 
A total of 85 subjects (27 in Room 1, 27 in Room 2, 31 in Room 3) were enrolled in the 
study and evaluated by three or four dermatologists. Demographic and clinical details for 
all subjects can be found in Table 7.  
 
Inter-rater reliability was high for both scale and erythema 
Descriptive statistics for inter-rater reliability (IRR) for scale and erythema can be found 
in Figure 13. Across all rooms, the scores were found to be highly correlated for both  
scale and erythema, with ICCs near or greater than 0.7. The inter-rater reliability for 
scale was generally greater than that for erythema. The scores in Room 1 showed the 
highest degree of inter-rater reliability, with ICCs greater than 0.7 for both scale and 
erythema for all 4 body sites.   
  
Raters were consistent in choosing the specific set of scale standards for a given subject 
Similar to the data from validation on test photographs discussed above, the raters were 
consistent in choosing the specific set of scale standards (“L” or “K”) for a given subject. 
The inter-rater reliability was high with Kuder-Richardson Formula 20 greater than 0.77 
for all body sites Table 8. In room 2, all of the raters unanimously agreed on “L” or “K” 
for all of the subjects seen (Kuder-Richardson Formula 20 of 1).  
 
Inter-rater reliability was high for the combined scores for scale and erythema, as well as 
the final total scores 
An important feature of the design of our index is the ability to allow for a comprehensive 
assessment of ichthyosis severity that accounts for the severities at the 4 representative 
sites. We determined IRR for the combined scores that range from 0 to 16 (score of 0-4 
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for each of 4 body sites) for each category (erythema and scale). We also determined 
IRR for the final score (sum of combined scores for scale and erythema) that ranges 
from 0 to 32. As shown in Figure 14, the inter-rater reliability was high, with ICCs 
consistently higher than 0.7.  
 
Power analysis to predict sample size for 1-step improvement 
To determine the feasibility of using VIIS in future clinical trials, we performed a power 
analysis to determine the number of subjects that would need to be enrolled to detect a 
single step improvement or decrement on our 5-step scale. For our cohort of 85 
subjects, the mean scores for erythema and scale are 1.78 and 2.35, respectively, 
across all body sites. In many clinical trials, inclusion criteria require subjects to start with 
a severity of at least 2 to measure a 1-2 step improvement. Approximately 50% and 70% 
of subjects had scores greater than or equal to 2 for erythema and scale, respectively. 
For subjects with average scores greater than or equal to 2, the mean score was 2.8 
with standard deviation of 0.7. Given the null hypothesis that the control and treatment 
groups have equal means of 2.8, the alternative hypothesis that the mean of the 
treatment group is 1.8 (1 unit difference), and an estimated group standard deviations of 
0.7, a sample sizes of 12 in the control group and 12 in the treatment group will achieve 
92% power to detect a one unit difference.  
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Table 7. Demographic and clinical characteristics for patients enrolled in the 
second stage of validation at the FIRST conference (n=85) 
Abbreviations: EI, Epidermolytic Ichthyosis; LI, Lamellar Ichthyosis; CIE, Congenital 
Icthyosiform Erythroderma; HI, Harlequin Ichthyosis; IWC, Ichthyosis With Confetti; EKV, 
Erythrokeratoderma Variabilis. 
 
		 		 Room	1	 Room	2	 Room	3	 Total	
	 	 	 	 	 n	 %	
Gender	 Male	 12	 16	 11	 39	 45.9%	
		 Female	 15	 11	 20	 46	 54.1%	
		 		 		 		 		 		 		
Ethnicity	 Caucasian	 21	 19	 26	 66	 77.6%	
		 Hispanic/Latino	 2	 1	 2	 5	 5.9%	
		 Black	 1	 1	 0	 2	 2.4%	
		 Asian	 2	 4	 1	 7	 8.2%	
		 Unknown	 1	 2	 2	 5	 5.9%	
		 		 		 		 		 		 		
Age	 ≥	18	yrs	 19	 14	 9	 42	 49.4%	
		 <	18	 6	 8	 21	 35	 50.6%	
		 		 		 		 		 		 		
Ichthyosis	Type	 EI	 6	 6	 9	 21	 24.7%	
		 ARCI	 9	 8	 13	 30	 35.3%	
		 Netherton's	 0	 2	 4	 6	 7.1%	
		 X-linked	ichthyosis	 1	 1	 0	 2	 2.4%	
		 Ichthyosis	vulgaris	 1	 1	 1	 3	 3.5%	
		 HI	 0	 2	 1	 3	 3.5%	
		 IWC	 2	 0	 0	 2	 2.4%	
		 EKV	 1	 0	 0	 1	 1.2%	
		 KID	syndrome	 1	 0	 0	 1	 1.2%	
		 Unclassified	 6	 7	 3	 16	 18.8%	
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Figure 13. IntraClass Correlation Coefficients (ICCs) for agreement and 
consistency for the three rooms during in-person evaluations at the FIRST 
conference (Stage 2) 
For all rooms, the ratings were found to be highly correlated for scale and erythema 
(ICCs near 0.7 or greater).  
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 ROOM 1 ROOM 2 ROOM 3 
Dorsal Foot 0.85 (0.72, 0.92) 1.00 (1.00, 1.00) 0.94 (0.89, 0.97) 
Lower Leg 0.85 (0.73, 0.92) 1.00 (0.99, 1.00) 0.92 (0.87, 0.96) 
Upper Arm 0.77 (0.59, 0.88) 1.00 (0.99, 1.00) 0.92 (0.87, 0.96) 
Upper Back 0.83 (0.69, 0.91) 1.00 (1.00, 1.00) 0.92 (0.86, 0.96) 
 
Table 8. Kuder-Richardson Formula 20, KR20, values for the three rooms during 
in-person evaluations at the FIRST conference (Stage 2) 
Raters were consistent in choosing the specific set of standards for scale (“L” or “K”) for 
a given patient, with KR20 greater than 0.77 for all body sites. 
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Figure 14. IntraClass Correlation Coefficients (ICCs) for agreement and 
consistency for the combined scores for scale and erythema, as well as the final 
total scores during in-person evaluations at the FIRST conference (Stage 2) 
For all rooms, the ratings were found to be highly correlated for hyperkeratosis and 
erythema (ICCs greater than 0.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.6   0.8 0.6   0.8 0.6   0.8 
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DISCUSSION 
We have designed and validated a visual severity index for ichthyosis, a critical tool for 
research and clinical evaluation in this rare group of disorders. The Congenital 
Ichthyosis Severity Index (CISI) is the only other ichthyosis severity index to have 
undergone validation. Similar to our instrument, the CISI employs visual Likert scales for 
scale and erythema.72 We aimed to improve the convenience and applicability of the 
index by providing 1) clear written descriptions of the features characteristic of each level 
of scale 2) visual standards for four different body sites, and 3) two different sets of scale 
standards to account for two different types of scale seen in subjects with ichthyosis.  
 
To create a user-friendly index, we focused on two different types of scale (lamellar and 
keratoderma), instead of creating a separate standard for each subtype of ichthyosis as 
was done for the CISI.80 We found high inter-rater and intra-rater ICCs for scale (near 
0.7 or greater for all rounds of testing). Raters were highly consistent in deciding which 
set of scale standards to choose for a given subject (Kuder-Richardson Formula 20 
greater than 0.77 for all rounds of testing), even though our subject population was 
heterogeneous with respect to clinical diagnosis (Table 5 and Table 7).  Subgroup 
analysis revealed that high ICCs for scale were maintained even in the rare cases where 
raters disagreed on which set of standards to use for a given subject; that is, ICCs for 
subjects for whom all the raters unanimously chose the same set of standards did not 
differ significantly from ICCs for subjects for whom raters chose differently. This 
indicates that our two different sets of scale standards capture increments of severity in 
a similar fashion, possibly due to the detailed written descriptions that standardize the 
scoring regardless of which set of standards is used. This suggests that the 
standardized written descriptions may allow or even be critical for scoring of the many 
different clinical subtypes of ichthyosis—even those not represented in the photographs.  
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While the inter-rater reliability for erythema was high (ICCs near 0.7 or greater) during in-
person validation at the FIRST conference, it was poor (ICCs less than 0.6) during 
validation on test photographs. This finding emphasizes the difficulty of capturing and 
reproducing erythema on photographic images. Many factors, including room lighting 
and color saturation settings, can impede consistent evaluation of erythema on 
photographs. 
 
Much literature has been published on evaluation of erythema, with compelling evidence 
for the use of both visual analog scales, and more objective methods, such as 
reflectance spectrophotometry. Reflectance spectrophotometry calculates an erythema 
index by comparing the intensity of light absorbed by hemoglobin (green light) to that of 
light absorbed by melanin (red light). Several studies have provided evidence for the 
reliability of reflectance spectrophotometry;77,78 however, others have shown lack of 
superiority of readings from a reflectance spectrophotometry compared to visual analog 
scales.75, 82 Various operator factors can influence the reading obtained from reflectance 
spectrophotometry, including the pressure with which the instrument is held and the 
angle used.83 Furthermore, several individual factors can impact reflectance 
spectrophotometry readings, including blood pressure, smoking, caffeine intake, and 
skin phototype.83,84 Latreille et al. showed that erythema induced by methyl nicotinate 
was not detected by reflectance spectrophotometry in the darker phototypes, possibly 
because the emitted light is predominantly absorbed by the melanin in the epidermis and 
does not reach the hemoglobin in the dermis.84 Given the time- and cost-effectiveness of 
visual observation, and lack of strong evidence for the superiority of reflectance 
spectrophotometry, we utilized a visual analog scale for the evaluation of erythema in 
our index.  
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During in-person evaluation, our index showed high inter-rater reliability for both 
erythema and scale with ICCs near 0.7 and greater. An important feature the VIIS is its 
flexibility in either evaluating the severity at a specific individual body site, as may be 
done in a clinical trial, or utilizing ratings of all 4 body sites to arrive at a comprehensive 
assessment of ichthyosis severity. Our analysis showed high inter-rater reliability for 
both the individual ratings for each body site, as well as the combined scores.  
 
A limitation of our index is that the photographs included in the standards were from 
subjects with Fitzpatrick I-III skin type. As shown in Table 5 and Table 7, the majority of 
the subjects during the validation process were Caucasian. Ideally, visual standards 
would have been created for a range of skin phototypes. We aimed to increase the 
generalizability of our instrument while maintaining convenience by including written 
descriptions for each level for severity that are applicable to all skin types. Further 
studies will be necessary to determine whether our standards can be reliably used for 
Fitzpatrick IV-VI skin types, especially for erythema since evaluation of erythema can be 
more challenging in individuals with darker phototypes.  
 
We have designed a Visual Index for Ichthyosis Severity (VIIS), and performed several 
rounds of rigorous validation to show high reliability and reproducibility. Such a 
standardized method of assessing disease severity has the potential to advance 
ichthyosis research. This user-friendly index was easily applied by dermatologists during 
a busy schedule of clinical evaluations at the FIRST conference, and with high ICCs for 
evaluation of scale and erythema. Our analysis also indicates that to reliably capture all 
aspects of the index, it is essential that the evaluations be performed in person. This 
finding is critical to the study design of clinical trials and emphasizes the importance of 
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in-person evaluations rather than assessments of photographs, especially when 
erythema is one of the outcome measures. In addition, power analysis revealed that a 
sample size of 24 (12 in control group, 12 in treatment group) will achieve 92% power in 
detecting a unit difference, which is a feasible sample size. We expect this index to 
facilitate clinical phenotyping and to provide a measure of response for therapeutic trials 
which assess the cardinal features of this class of disorders. 
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